Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
IMFINZI offers Q4W fixed dosing1§ and should be initiated within 42 days commencing from the last day of the final cycle of chemoradiation therapy (CRT) or the last day of radiotherapy1,2,6
*The ADRIATIC trial investigated durvalumab following cCRT only. However, NICE and SMC recommend durvalumab for use following either sCRT or cCRT for the management of LS-SCLC.2,4,6
§ Infuse IMFINZI for up to 24 months or until disease progression or unacceptable toxicity.1
† 60 to 66 Gy once daily (QD) over 6 weeks or 45 Gy twice daily (BID) over 3 weeks.1
‡ Patients must have achieved CR, PR, or SD, and have not progressed following cCRT.6
¶ Refer to Prescribing Information for information on dosage modifications.
*Different doses were studied in the ADRIATIC trial of either 60 to 66 Gy over 6 weeks (standard once-daily schedule) or 45 Gy over 3 weeks (hyperfractionated twice-daily schedule).6
†In the ADRIATIC trial, 88.3% of patients received 4 cycles of chemotherapy.6
*Different doses were studied in the ADRIATIC trial of either 60 to 66 Gy over 6 weeks (standard once-daily schedule) or 45 Gy over 3 weeks (hyperfractionated twice-daily schedule).6
†In the ADRIATIC trial, 88.3% of patients received 4 cycles of chemotherapy.6
The NICE recommended and SMC accepted IMFINZI ADRIATIC regimen offers the solution of PCI alongside sCRT or cCRT.2,4,6
Hear Dr Huiqi Yang, Consultant Clinical Oncologist, Cambridge University Hospitals NHS Foundation Trust share her insights on the practicalities of delivering PCI in a real-world setting.
All statements and opinions expressed in this video are those of the individual speaker and are based on their own personal experience.
For detailed instructions on preparation of solution please see below or refer to section 6.6 of the IMFINZI Summary of Product Characteristics.1
Administer the infusion solution intravenously over 1 hour through an intravenous line containing a sterile, low-protein binding 0.2 to 0.22 μm in-line filter.1
Do not co-administer other medicinal products through the same infusion line.1
For treatment modifications for IMFINZI please refer to section 4.2 in the SmPC.1
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.1
When IMFINZI is administered in combination with chemotherapy, administer IMFINZI prior to chemotherapy on the same day.1
The safety and efficacy of IMFINZI monotherapy in children and adolescents aged below 18 years of age has not been established regarding NSCLC. No data are available. For more information, please see section 5.1 and 5.2 of the IMFINZI Summary of Product Characteristics.1
No dose adjustment is required for elderly patients (≥65 years of age). For more information, please see section 5.1 of the IMFINZI Summary of Product Characteristics.1
No dose adjustment of IMFINZI is recommended in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions on this population. For more information, please see section 5.2 of the IMFINZI Summary of Product Characteristics.1
Data from patients with severe hepatic impairment are limited. Due to minor involvement of hepatic processes in the clearance of durvalumab no dose adjustment of IMFINZI is recommended for patients with hepatic impairment as no difference in exposure is expected. For more information, please see section 5.2 of the IMFINZI Summary of Product Characteristics.1
For the full list of special warnings and precautions, please see section 4.4 of the IMFINZI Summary of Product Characteristics.
In patients with pre-existing AID, data from observational studies suggest an increased risk of immune-related adverse reactions following immune-checkpoint inhibitor therapy as compared with patients without pre-existing AID. In addition, flares of the underlying AID were frequent, but the majority were mild and manageable.1
Patients with the following were excluded from clinical trials: a baseline ECOG performance score ≥2; active or prior documented autoimmune disease within 2 years of initiation of the study; a history of immunodeficiency; a history of severe immune-mediated adverse reactions; medical conditions that required systemic immunosuppression, except physiological dose of systemic corticosteroids (≤10 mg/day prednisone or equivalent), uncontrolled intercurrent illnesses; active tuberculosis or hepatitis B or C or HIV infection or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI. In the absence of data, IMFINZI should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.1
For more information on exclusion criteria for each specific study see section 5.1.
IMFINZI is supplied as single-use vials, available in two dosage strengths: either 120 mg/2.4 mL (50 mg/ml) or 500 mg/10 mL (50 mg/mL).1
Inside is a clear-to-opalescent, colourless-to-slightly yellow solution in a type glass 1 vial with an elastomeric stopper and a grey flip-off aluminium seal for 2.4 ml vials or a white flip-off aluminium seal for 10 ml vials.1
The drug product must be visually inspected, and the vial must be discarded if the solution is cloudy, discoloured, or visible particles are observed prior to administration.1
Shelf life: 3 years.1
Store in refrigerator (2 ˚C – 8 ˚C).1
Do not freeze.1
Store in the original package in order to protect from light.1
Chemical and physical in-use stability has been demonstrated for up to 30 days at 2 ˚C – 8 ˚C and for up to 24 hours at room temperature (up to 25 ˚C) from the time of preparation.1
The prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 ˚C – 8 ˚C or 12 hours at room temperature (up to 25 ˚C), unless dilution has taken place in controlled and validated aseptic conditions.1
IMFINZI is supplied as a single-dose vial and does not contain any preservatives, aseptic technique must be observed.1
Get to know the ADRIATIC safety profile
Take a closer look at how IMFINZI works within the ADRIATIC Regimen
Discover more about the ADRIATIC study design and efficacy outcomes
GB-76777 | DOP: September 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
GB-74216| DOP : February 2026
